Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia

Haematologica

Volumn 92, Issue 9, 2007, Pages 1216-1223

  Torres, Harrys A ^a   Aguilera, Elizabeth A ^a   Mattiuzzi, Gloria N ^a   Cabanillas, Maria E ^a   Rohatgi, Nidhi ^a   Sepulveda, Carmen A ^a   Kantarjian, Hagop M ^a   Jiang, Ying ^a   Safdar, Amar ^a   Raad, Issam I ^a   Chemaly, Roy F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aerosolized ribavirin; Leukemia; Pneumonia; Respiratory syncytial virus

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; PALIVIZUMAB; RIBAVIRIN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AEROSOL; AGED; APACHE; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CONTINUOUS INFUSION; DEATH; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; FEMALE; HUMAN; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MORBIDITY; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE; SALVAGE THERAPY; TIME SERIES ANALYSIS; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; LEUKEMIA; MALE; MIDDLE AGED; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RIBAVIRIN; SURVIVAL RATE; TIME FACTORS;

EID: 36348956173     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11300     Document Type: Article

References (27)

1. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85:278-87.
2. Hicks KL, Chemaly RF, Kontoyiannis DP. Common community respiratory viruses in patients with cancer: more than just common colds. Cancer 2003;97:2576-87.
3. Whimbey E, Ghosh S. Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis 2000;20:232-55.
4. Whimbey E, Champlin RE, Couch RB, Englund JA, Goodrich JM, Raad I, et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996;22:778-82.
5. Ljungman P, Ward KN, Crooks BN, Parker A, Martino R, Shaw PJ, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001;28:479-84.
6. Machado CM, Boas LS, Mendes AV, Santos MF, da Rocha IF, Sturaro D, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003;31:695-700.
7. Ebbert JO, Limper AH. Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome. Respiration 2005;72:263-9.
8. Whimbey E, Englund JA, Couch RB. Community respiratory virus infections in immunocompromised patients with cancer. Am J Med 1997;102:10-8; discussion 25-6.
9. Ljungman P. Respiratory virus infections in bone marrow transplant recipients: the European perspective. Am J Med 1997;102:44-7.
10. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987-93.
11. Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:321-7.
12. Whimbey E, Champlin RE, Englund JA, Mirza NQ, Piedra PA, Goodrich JM, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995;16:393-9.
13. Champlin RE, Whimbey E. Community respiratory virus infections in bone marrow transplant recipients: the M.D. Anderson Cancer Center experience. Biol Blood Marrow Transplant 2001;7 Suppl:8S-10S.
14. Anaissie EJ, Mahfouz TH, Aslan T, Pouli A, Desikan R, Fassas A, et al. The natural history of respiratory syncytial virus infection in cancer and transplant patients: implications for management. Blood 2004;103:1611-7.
15. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect on engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003;32:195-203.
16. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis 2007;44:245-9.
17. Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995;21:376-9.
18. Field K, Slavin MA, Seymour JF. Severe respiratory syncytial virus pneumonia complicating fludarabine and cyclophosphamide treatment of chronic lymphocytic leukemia. Eur J Haematol 2002;69:54-7.
19. Eftekhari P, Lassoued K. Oksenhendler E, Scieux C, Clauvel JP. Severe respiratory syncytial virus pulmonary infection in a patient treated with fludarabine for chronic lymphocytic leukemia. Ann Hematol 1998;76:225-6.
20. Black CP. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 2003;48:209-31; discussion 31-3.
21. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40.
22. Shults RA, Baron S, Decker J, Deitchman SD, Connor JD. Health care worker exposure to aerosolized ribavirin: biological and air monitoring. J Occup Environ Med 1996;38:257-63.
23. Ghosh S, Champlin RE, Englund J, Giralt SA, Rolston K, Raad I, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000;25:751-5.
24. Ghosh S, Champlin RE, Ueno NT, Anderlini P, Rolston K, Raad I, et al. Respiratory syncytial virus infections in autologous blood and marrow transplant recipients with breast cancer: combination therapy with aerosolized ribavirin and parenteral immunoglobulins. Bone Marrow Transplant 2001;28:271-5.
25. Asian T, Fassas AB, Desikan R, Siegel D, Munshi N, Mehta J, et al. Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy. Bone Marrow Transplant 1999;24:505-9.
26. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH, Jr. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience. Bone Marrow Transplant 2000;25:161-5.
27. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J, Corey L. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001;184:350-4.